Our results align with these findings; as a CX3CR1 antagonist, KAND567, inhibited the transition of CLL-related monocytes to NLCs and suppressed their CLL-supporting effect, leading to CLL cell apoptosis. This evidence concerns the gene CX3CR1 and B-cell chronic lymphocytic leukemia.